June 29, 2026 · Form 4 insider transaction
Dandekar Atul bought 7,500 shares of Maze Therapeutics, Inc. at $10.42 per share, a transaction worth $78.2K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.; The reported total includes 1,442 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).